Compounded GLP-1 Oral Solutions and Sublingual Drops: What They Are, FDA Status and Risks

Search for a needle-free GLP-1 and you will quickly find “oral semaglutide solution,” “GLP-1 drops,” “sublingual semaglutide” and even “GLP-1 oral liquid” kits sold through online programs. They promise the benefits of the famous weekly shots in a few drops under the tongue. It sounds simple, but these products sit in a very different place, scientifically and legally, from the GLP-1 medicines tested in the big clinical trials.

This guide explains what compounded GLP-1 oral solutions and drops are, where they stand with the FDA, what the absorption research actually shows, who sets the instructions for taking them, and the specific risks to understand before you use one. It is general education, not medical advice. Your own prescriber and pharmacist should guide any treatment decision.

The short answer

• What they are: liquids or drops prepared by compounding pharmacies, usually containing semaglutide (occasionally tirzepatide), meant to be swallowed or held under the tongue.
• FDA status: not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Every FDA-approved oral GLP-1 is a tablet.
• Evidence: no published human trial shows how much drug a compounded drop delivers, what dose is right or how much weight people lose. The data so far come from a lab tissue model and studies in rats.
• Instructions: there is no official label. Only your prescriber’s written directions and the pharmacy label apply, and FDA tells patients to ask the compounder or telehealth platform about instructions for use.
• Main risks: unclear strength, dosing errors, unknown ingredients or salt forms, fraudulent products and a lack of follow-up care.
• Expert view: the American Diabetes Association (ADA) recommends against non-FDA-approved compounded GLP-1 products because of uncertainty about what they contain.

What exactly is a “GLP-1 oral solution”?

GLP-1 medicines such as semaglutide and tirzepatide copy, or build on, a gut hormone that helps control appetite, fullness and blood sugar. Our guide to how GLP-1s work for weight loss covers the biology. The approved products come as weekly injections or, for semaglutide and the newer pill Foundayo, as daily tablets.

A compounded drug is one a pharmacist mixes or alters for a patient, instead of a factory-made product that went through FDA approval. FDA explains that compounding has legitimate uses. One example is a patient who needs a liquid because they cannot swallow a tablet. Another is someone who is allergic to a dye in the approved version.

The products marketed online fall into a few groups:

Product type	How it is taken	FDA-approved version exists?
Oral solution or liquid	Measured with a syringe or dropper and swallowed	No
Sublingual drops	Held under the tongue for a set time, then swallowed	No
Dissolving tablets, troches or lozenges	Dissolved in the mouth	No
“GLP-1” supplements, patches or drops sold without a prescription	Varies	No, and these usually contain no actual GLP-1 drug
Wegovy pill, Rybelsus, Ozempic tablets, Foundayo	Swallowed whole as a tablet	Yes

Labels such as “oral semaglutide” or “GLP-1” on a compounded liquid do not make it the same product as the approved tablets. FDA has repeatedly warned online companies against claiming or implying that compounded versions are the same as FDA-approved drugs. If you want the full picture on the approved options, see oral semaglutide explained and orforglipron explained.

Why a peptide is so hard to give by mouth

Semaglutide is a peptide, a short chain of amino acids. Your digestive system is designed to break peptides down into pieces, the same way it digests protein from food. Peptides are also large molecules that do not pass easily through the lining of the gut or the mouth.

That is why semaglutide was first sold as an injection. It took years of engineering to turn it into a tablet. The approved tablets pair semaglutide with an absorption enhancer called SNAC and come with a strict routine: an empty stomach, a small sip of water and a wait before eating. Even with all that, only a tiny fraction of each tablet reaches the bloodstream, about 1% or less according to the labels. That is why tablet doses are measured in tens of milligrams while weekly injection doses are a few milligrams. We explain the details in our oral semaglutide guide.

A compounded liquid or drop is a different formulation. It does not contain the approved tablet’s carefully tested design, and its absorption has never been measured in a human trial. So nobody can say, from published data, how much drug a given number of drops delivers to the blood.

What the research on sublingual semaglutide actually shows

We searched PubMed and other sources in October 2026 for human studies of compounded oral or sublingual semaglutide. We found none: no blood-level studies in people, no dose-finding studies and no weight-loss trials. Here is what does exist.

A lab study in tissue samples

A technical report from a compounding supplier tested a sublingual semaglutide formula on lab-grown human mouth and gum tissue. Semaglutide passed into and through the tissue within minutes. Lab tissue models are an early screening step, though. They cannot tell you how much drug reaches the blood in a living person.

Rat studies

The most useful data so far is a peer-reviewed study in rats, published in the European Journal of Pharmaceutical Sciences in December 2025. Researchers compared semaglutide given under the tongue, swallowed and injected:

Route in rats	Relative bioavailability vs injection
Swallowed, 1 mg/kg	0.06%
Swallowed, 20 mg/kg	0.16%
Sublingual, from tablets	0.34%
Sublingual, from powder	0.29%

In plain terms, the rats absorbed under the tongue only about 3 to 4 thousandths of what an injection delivered. That was more than they absorbed by swallowing, and blood levels varied less. The authors called it a proof-of-concept study that supports more research in humans. It does not show that drops work in people, and it gives no basis for a human dose.

A related technical report from the same supplier said directly that its rat study “is not intended to provide guidance on the sublingual dosing of semaglutide” in humans, or on converting doses from injections or tablets to drops. It said human pharmacokinetic and dose-finding studies are needed.

What that means for you

If a product page shows weight-loss percentages from the big injection or tablet trials next to a bottle of drops, those numbers belong to different products. The honest summary is that sublingual semaglutide may reach the bloodstream in small amounts. Whether a specific compounded drop delivers a consistent, effective and safe amount in people is unknown.

Some physicians on X make the same point. In an October 2026 thread on the oral semaglutide trial, one doctor noted that online “oral semaglutide” drops “are not what was studied.”

FDA status: where compounded GLP-1 liquids stand in 2026

Compounded drugs are not FDA-approved

FDA’s guidance is clear: compounded drugs are not FDA-approved, FDA does not verify their safety, effectiveness or quality before marketing, and they are not the same as generic drugs, which are approved. FDA says compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug.

The shortages are over

During the shortages of 2022 to 2024, federal law let compounders make copies of semaglutide and tirzepatide injections because the approved products were on FDA’s shortage list. That changed in early 2025:

• Tirzepatide: FDA removed it from the shortage list in late 2024. The grace period for state-licensed pharmacies ended in early 2025, and the one for larger outsourcing facilities ended on March 19, 2025.
• Semaglutide: On February 21, 2025, FDA declared the semaglutide injection shortage resolved. The grace period for state-licensed pharmacies has ended (FDA confirmed this in an April 2025 update). For outsourcing facilities it ran until May 22, 2025.

After the shortages ended, compounders could no longer make products that are “essentially a copy” of the approved drug. Federal law treats a compounded product as not a copy only when it is changed for an identified individual patient and the prescriber has determined that the change will make a significant difference for that patient. FDA guidance quoted by the Kentucky Board of Pharmacy adds that a lower price is not enough to meet that test. Some sellers argue that a liquid or drop is a different product from an injection. Whether a particular prescription meets the legal test depends on the facts of that patient’s case, not on the marketing.

Salt forms

FDA has warned that some compounded semaglutide uses salt forms such as semaglutide sodium or semaglutide acetate. FDA says these are different active ingredients from the approved drugs, it has no information on whether they behave the same way, and it is “not aware of any lawful basis for their use in compounding.” This matters for oral products because the form and purity of the ingredient may affect how it is absorbed.

Crackdown on marketing

FDA has stepped up enforcement against telehealth marketing of compounded GLP-1s. A wave of warning letters began in September 2025, and FDA says thousands of letters went out over the following six months. On March 3, 2026, FDA announced 30 more warning letters to telehealth companies. The main problems it found were claims implying sameness with FDA-approved products and products branded with the telehealth company’s own name in a way that hid who actually compounded them. In June 2026, Reuters reported a further 25 letters, including companies claiming their compounded drugs came from “FDA approved pharmacies” or that their ingredients were “clinically studied.”

Safety reports

FDA says that as of May 31, 2026, it had received 990 adverse event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. Pharmacies that are not outsourcing facilities do not have to report adverse events to FDA, so these numbers are likely undercounts.

How to take a GLP-1 oral solution: who sets the instructions

People often search for exactly this question, and the honest answer is that no official instructions exist. An FDA-approved drug comes with a label that has been reviewed, explaining the dose, timing, food rules and what to do about a missed dose. A compounded GLP-1 liquid has none of that. The directions on your bottle come from your prescriber and the pharmacy that made it. They are not based on a human trial of that product.

We do not give dosing advice. Here is how to stay safe with any instructions you are given:

1. Use only your own prescriber’s written directions and the pharmacy label. Never follow a dose chart from social media, a forum, a group chat or another patient’s bottle. Strengths differ between pharmacies, so the same number of drops can contain very different amounts of drug.
2. Know the strength in milligrams per milliliter. Ask the pharmacist to confirm it, and to show you how to measure one dose with the exact dropper or oral syringe supplied.
3. Watch the units. Confusion between milligrams, milliliters, “units,” “clicks” and drops is a known cause of GLP-1 dosing errors.
4. Do not change the amount, frequency or route yourself, and do not combine a compounded product with any other GLP-1 medicine.
5. Ask about timing. Approved oral semaglutide has strict food, drink and medicine rules because those affect absorption. Ask your prescriber how a compounded liquid should be timed and whether it could affect your other medicines.
6. Contact the compounder or telehealth platform with questions. This is FDA’s own advice for questions about instructions or labels. A legitimate program should have a licensed clinician you can reach after your medicine arrives.

Our guide to how telehealth weight-loss programs work explains what a proper online assessment and follow-up should look like.

The main risks, explained

Dosing errors

FDA has received multiple reports of adverse events, some needing hospital care, linked to dosing errors with compounded semaglutide. These involved patients measuring the wrong amount and, in some cases, clinicians miscalculating doses. The ADA statement says reported errors ranged from 5 to 20 times the intended dose, often because of confusion between milliliters, milligrams and “units.”

A poison control case series summarized in the American Journal of Managed Care gives a feel for how this happens. One person took 50 units instead of 5 from a vial with no concentration on the label. Another took 1 mL instead of 0.1 mL. Those cases involved injections, but the same problem applies to liquids measured with droppers or oral syringes: when the strength is unclear and the units are confusing, a tenfold mistake is easy to make.

FDA has also received reports of people being prescribed compounded semaglutide or tirzepatide at doses beyond the approved labels, or with faster dose increases. Some of them needed medical attention for nausea, vomiting, diarrhea, stomach pain and constipation.

Unknown or variable ingredients

There is no official standard (a USP monograph) for compounding semaglutide or tirzepatide, the ADA notes. So each pharmacy picks its own formula. A compounded liquid may vary in:

• the form of the drug (base or a salt form),
• the liquid, oil or “self-emulsifying” base used to carry it,
• absorption enhancers, flavorings, sweeteners and preservatives,
• added ingredients such as vitamin B12 or B6, which change the formula in untested ways.

For comparison, the approved Wegovy tablet lists just semaglutide, SNAC and magnesium stearate. If you have allergies, ask for the complete ingredient list. The ADA advises not using any product whose label does not state the exact contents and the dose with units.

Fraudulent and “research-only” products

FDA is aware of fraudulent compounded semaglutide and tirzepatide with labels naming pharmacies that do not exist, or real pharmacies that never made the product. It has also warned sellers that market GLP-1 drugs as “for research purposes” or “not for human consumption” while selling them to consumers with dosing instructions. The ADA statement notes that clinicians have seen patients arrive with oral and sublingual GLP-1 products, dosage forms that do not exist for the approved drugs, and with unapproved compounds such as retatrutide. FDA says retatrutide cannot legally be used in compounding at all. Our guide to red flags for online GLP-1 sellers shows how to spot these sellers.

Gaps in follow-up care

The ADA points out that online prescribers and compounding pharmacists may not have your full medical history, list of medicines or family history, and may not be involved in ongoing monitoring. That matters because GLP-1 medicines can interact with diabetes medicines, raising the risk of low blood sugar, and they carry warnings about pancreatitis, gallbladder disease and thyroid tumors. Read who should not take GLP-1s and semaglutide side effects for the full picture.

Uncertain effect

If a drop delivers too little drug, you may spend money and months on a product that does very little. If one batch is stronger than the last, you may suddenly get stronger side effects. Both are real possibilities when absorption and strength have not been standardized.

Questions to ask before using a compounded oral GLP-1

1. Is the active ingredient semaglutide (or tirzepatide) itself, or a salt form?
2. Which state-licensed pharmacy or FDA-registered outsourcing facility makes it, and can I check its license? (The ADA suggests checking FDA’s list of registered outsourcing facilities or your state’s licensed pharmacy directory.)
3. What is the exact strength in mg per mL, and how do I measure one dose?
4. What evidence shows this route gets the drug into the bloodstream in people?
5. Why is a compounded product medically necessary for me instead of an FDA-approved option?
6. What is the full ingredient list, including the base and any added vitamins?
7. Who do I contact about side effects, and how quickly do they respond?
8. How should I store it, and when does it expire?

If the answers are vague, or the seller will not tell you who compounded the product, treat that as a warning sign.

Needle-free alternatives that are FDA-approved

If the main appeal of drops is avoiding injections, FDA-approved tablets now exist. The Wegovy pill (oral semaglutide 25 mg) is approved for chronic weight management. Foundayo (orforglipron) is a small-molecule GLP-1 pill that can be taken without food or water restrictions. Both were tested in large trials, and their labels spell out the dose, timing and side effects. Our comparison of GLP-1 pills vs injections and our list of FDA-approved GLP-1s for weight loss walk through the options.

Cost is often the real reason people look at compounded products. Self-pay prices for the approved medicines have changed a lot recently. Our guides to semaglutide cost without insurance and whether insurance covers GLP-1s cover the current numbers. Bring them to your prescriber before deciding.

What people are saying online

On X and YouTube, posts about GLP-1 drops split into two camps. Sellers and some patients describe drops as an easy, needle-free version of the injections, often with discount codes and before-and-after photos. Physicians and pharmacists posting on the topic tend to stress the gap in evidence. They point out that the trial results come from approved injections and tablets, that absorption through the mouth has not been measured in people and that dose charts passed around online have no tested basis.

Neither personal stories nor marketing can stand in for a trial. When a product has not been tested in people, nobody can promise how it will work for you.

How to report a problem

If you have side effects or notice a quality problem, such as a cloudy or discolored liquid, a missing strength on the label or a damaged package, tell your prescriber. Get urgent care for severe stomach pain, signs of an allergic reaction or vomiting so bad you cannot keep fluids down. You can also report the problem to FDA through MedWatch online or by calling 1-800-FDA-1088. In the US, the Poison Help line is 1-800-222-1222 if you think you took too much.

The bottom line

Compounded GLP-1 oral solutions and sublingual drops are not FDA-approved, and their claims run ahead of the science. The approved GLP-1 pills needed years of engineering to get a small fraction of the drug through the gut. For compounded drops, the only absorption data are a lab tissue test and rat studies, with no human evidence of the right dose or of weight loss. No official instructions exist, so the strength and directions on your bottle come only from your prescriber and the pharmacy.

If you are considering one, check who makes it, what exactly is in it and why an approved option will not work for you. Measure carefully, and keep a clinician involved. Explore more needle-free options in our Oral and New GLP-1s hub.

Medical disclaimer: This article is for general education and is not medical advice. It does not replace a consultation with a licensed clinician who knows your health history. Do not start, stop or change any medicine without talking to your prescriber or pharmacist.